Adding Pembrolizumab to Chemotherapy Increases Pathological Complete Response, Improves Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2– Breast Cancer

Publication
Article
Pharmacy Practice in Focus: OncologyJanuary 2024
Volume 6
Issue 1

pCR rates improve regardless of whether patients received full chemotherapy doses.

New data from the KEYNOTE-756 trial (NCT03725059) of pembrolizumab (Keytruda; Merck) found that adding the immune checkpoint inhibitor to chemotherapy significantly increased the pathological complete response (pCR) rate and shifted residual cancer burden (RCB) to lower categories in patients with early-stage, high-risk estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancer. The data were presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) in Texas.

Nurse connecting an intravenous drip -- Image credit: satyrenko | stock.adobe.com

Image credit: satyrenko | stock.adobe.com

“Although patients with early-stage ER+, HER2–breast cancer generally have a better prognosis than those with other breast cancer subtypes, there is a high-risk subpopulation for whom neoadjuvant chemotherapy is indicated,” said presenter Joyce O'Shaughnessy, MD, Celebrating Women Chair in Breast Cancer Research at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, and director, Breast Cancer Research Program, Texas Oncology, US Oncology, in Dallas, Texas. “Pembrolizumab combined with neoadjuvant chemotherapy improves pCR rates and event-free survival [EFS] in patients with early-stage breast cancer.”

Findings from the phase 3 KEYNOTE-756 study demonstrated that among patients with high-risk, high-grade, and early-stage ER+, ER2– breast cancer, the addition of pembrolizumab to neoadjuvant chemotherapy led to a statistically significant increase in pCR in the intent-to-treat (ITT) population, regardless of tumor PD-L1 status. In the trial, eligible patients were randomly assigned 1:1 to receive neoadjuvant pembrolizumab 200 mg once every 3 weeks or placebo, both given with paclitaxel once every week for 12 weeks followed by 4 cycles of doxorubicin or epirubicin plus cyclophosphamide. After definitive surgery with or without radiation therapy, patients received pembrolizumab or placebo for 9 cycles in addition to standard endocrine therapy.

Patients were stratified based on region (Eastern Europe, China, or other), tumor PD-L1 status, nodal involvement, ER positivity, and anthracycline schedule. Dual primary end points were pCR and EFS. Secondary end points included overall survival, safety, and pCR defined as the absence of invasive tumor cells in the breast and axillary lymph nodes (ypT0 ypN0 and ypT0/Tis). RCB was an exploratory end point.

During the presentation at SABCS, O’Shaughnessy explained that 1278 patients were randomly assigned in the study. Approximately 2% of patients in both arms discontinued neoadjuvant therapy due to disease progression, 75% started adjuvant pembrolizumab, and 81% started adjuvant placebo. The study arms were generally well balanced regarding key characteristics such as age, PD-L1 activity, and geographic location. Additionally, 37% of patients had stage III disease and 90% had clinically node-positive disease, and 94% of the cancers had an ER expression of 10% or higher.

At the final pCR analysis, median followup was 33.2 months. In the ITT population, pembrolizumab plus chemotherapy showed a statistically significant improvement in pCR vs placebo plus chemotherapy at 24.3% and 15.6%, respectively. The results were consistent for the secondary pCR definitions ypT0 ypN0 (21.3% vs 12.8%, respectively) and ypT0/Tis (29.4% vs 18.2%, respectively).

Additionally, there were more patients with an RCB-0 score in the pembrolizumab arm compared with those in the placebo arm (24.7% and 15.6%, respectively) and more patients with an RCB-1 score (10.2% vs 8.1%, respectively). There were fewer patients in the RCB-2 (40.8% vs 45.3%, respectively) and RCB-3 (20.5% vs 28.9%, respectively) categories in the pembrolizumab group vs the placebo group.

Finally, in the neoadjuvant phase, grade 3 or higher treatment-related adverse event rates were 52.5% with pembrolizumab plus chemotherapy vs 46.4% with placebo and chemotherapy. There was 1 death in the pembrolizumab arm due to acute myocardial infarction.

O’Shaughnessy emphasized that increasing expression of PD-L1 was prognostic of higher pCR rates in both the placebo and pembrolizumab arms. Additionally, the majority of patients in each treatment arm (> 85%) received full chemotherapy exposure, but those who received less than the planned chemotherapy doses had poorer pCR rates. pCR rates were improved with the addition of pembrolizumab regardless of whether patients received the full chemotherapy doses.

Reference

O’Shaughnessy J. Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for late-stage high-risk ER+/HER2- breast cancer: KEYNOTE-756. Presented at: San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX.

Related Videos
Aimee Keegan, PharmD, BCOP, a clinical pharmacist
Aimee Keegan, PharmD, BCOP, a clinical pharmacist
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit: Sergey | stock.adobe.com - Unhappy woman with insomnia lying on bed next to alarm clock at night
© 2024 MJH Life Sciences

All rights reserved.